3 Results for "

2Carboxy-MMHP

" in MedChemExpress (MCE) Product Catalog:
Products (3)

3 Results for "2Carboxy-MMHP" in MCE Product Catalog:

Cat. No.: HY-W587411
CAS No.: 82975-93-7
Synonyms: Mono[2-(carboxymethyl)hexyl] phthalate; MCHP
Target:  

Drug Metabolite

Research Areas:  

Metabolic Disease

Mono[2-(carboxymethyl)hexyl] phthalate (MCHP) is a metabolite of Di-(2-ethylhexyl)phthalate (DEHP). DEH is an endocrine disrupting chemical that is widely used as the major plasticizer .
loading...
    loading...
Cat. No.: HY-114118S
Semaglutide-d8 is the deuterium labeled Semaglutide (HY-114118). Semaglutide is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer [2] .
loading...
    loading...
Cat. No.: HY-114118S1
Semaglutide-d8 tetraTFA is the deuterium labeled Semaglutide (HY-114118). Semaglutide is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer [2] .
loading...
    loading...